Gallium-68 DOTATOC
Alternative Names: 68Ga-DOTA(0)-phe(1)-tyr(3)-octreotide; 68Ga-DOTA-tyr3-Octreotide; 68Ga-DOTATOC; SomaKit-TOCLatest Information Update: 19 Jun 2025
At a glance
- Originator Unknown
- Developer Advanced Accelerator Applications; Icahn School of Medicine at Mount Sinai; Jiangsu Hengrui Medicine Co.; Turku University Hospital; University of Iowa
- Class Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Neuroendocrine tumours
- Phase III Myocarditis
- Phase II/III Glioma
Most Recent Events
- 22 Feb 2024 Phase-III clinical trials in Neuroendocrine tumours (Diagnosis) in China (Parenteral) (NCT06091748)
- 19 Oct 2023 Jiangsu HengRui Medicine plans a phase III trial for Neuroendocrine tumours (Diagnosis) in unknown location (NCT06091748)
- 07 Sep 2022 Gallium-68 DOTATOC is still in phase III trials for Myocarditis (Diagnosis) in France (IV) (EudraCT2019-002716-43)